Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genentech, Inc.
National Cancer Institute (NCI)
KaliVir Immunotherapeutics
M.D. Anderson Cancer Center
ImmunityBio, Inc.
University of Pittsburgh
LG Chem
Hoffmann-La Roche
Hoffmann-La Roche
Kymab Limited
Immatics US, Inc.
University of Colorado, Denver
Centre Hospitalier Universitaire de Besancon
invoX Pharma Limited
University Hospital, Essen
Rain Oncology Inc